Skip to content
Screener

NeoGenomics NEO Financing Cash Flow

Financing Cash Flow at other companies

Myriad Genetics logo
Myriad GeneticsMYGN
-$3M-122%
Labcorp Holdings logo
Labcorp HoldingsLH
-$919.9M-244%
Quest Diagnostics logo
Quest DiagnosticsDGX
-$229M+21.8%
Biodesix, Inc. logo
Biodesix, Inc.BDSX
$6.24M-36.3%
Personalis, Inc. logo
Personalis, Inc.PSNL
$17.83M-11.2%
Guardant Health logo
Guardant HealthGH
-$21.58M+67.7%

Other financials

Income statement

See full
Revenue$201.7M+11.2%
Gross profit$91.9M+18.9%
Operating income-$9.8M+79.5%
Net income$2.2M+105%
EPS (diluted)$0.02+106%

Balance sheet

See full
Cash & equivalents$145.5M-5.9%
Total debt$448.4M+534%
Total equity$785.7M-8.0%
Total assets$1.4B-3.0%

Cash flow

See full
Operating cash flow$20.0M-1.8%
CapEx$8.2M+30.0%
Free cash flow-$13.1M+56.0%

Valuation

See full
Market cap$2.13B+183%
Enterprise value$2.43B+264%
P/S2.8×+1.7×

Profitability

See full
Gross margin43.9%0.0pp
Operating margin-8.9%-2.8pp
Net margin-6.8%-2.4pp
FCF margin-4.9%

Returns & leverage

See full
Return on equity-6.3%-2.0pp
Debt / equity0.6×+0.5×
Current ratio3.6×-0.3×

Where this comes from

Reported directly by NeoGenomics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: NeoGenomics’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:09 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001077183-26-000059
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Proceeds from issuance of common stock under employee stock purchase plan1,7522,266
Proceeds from issuance of common stock upon exercise of stock options1,27374
Employee taxes paid related to net share settlement of restricted stock(3,168)(2,567)
Net cash used in financing activities(12,582)(201,484)
Net change in cash and cash equivalents, including cash classified within current assets held for sale(14,079)(212,235)
Less: net change in cash classified within current assets held for sale(54)
Net change in cash and cash equivalents(14,079)(212,289)
Cash and cash equivalents, beginning of period159,618367,012

Item 1. Financial Statements (unaudited)

FAQ

What is NeoGenomics's financing cash flow?
NeoGenomics (NEO) reported financing cash flow of -$12.24M in Q2 2026.
How has NeoGenomics's financing cash flow changed year-over-year?
NeoGenomics's financing cash flow increased by 94.0% year-over-year, from -$202.43M to -$12.24M.
What is the long-term trend for NeoGenomics's financing cash flow?
Over 3 years (2021 to 2024), NeoGenomics's financing cash flow has grown at a -81.5% compound annual growth rate (CAGR), from $732.01M to $4.65M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about NeoGenomics's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude